clinical trial · NCT06879145
Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316)
Suzhou Suncadia Biopharmaceuticals Co., Ltd.·phase3·recruiting·n = 840
Muscular Invasive Bladder Cancer (MIBC)SHR-A2102；Adebrelimab
brief summary
In phase II, the main objective is to evaluate the efficacy of SHR-A2102 combined with Adebrelimab in the treatment of muscular invasive bladder cancer (MIBC); The main objective of phase III is to evaluate the efficacy of SHR-A2102 for injection combined with Adebrelimab compared with gemcitabine combined with cisplatin in the treatment of muscular invasive bladder cancer (MIBC).
started
Apr 25, 2025
primary completion
Dec 1, 2031
completion
Dec 1, 2031
last updated
Jun 18, 2025
official title
A Randomized, Open, Multicenter Phase II/III Clinical Study of SHR-A2102 for Injection Combined With Adebrelimab (SHR-1316) in Perioperative Treatment of Muscular Invasive Bladder Cancer (MIBC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol